TAGRISSO® plus savolitinib demonstrated 49% objective r

TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

astrazeneca-us.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca-us.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Vienna , Wien , Austria , Canada , Seoul , Soult Ukpyolsi , South Korea , United States , United Kingdom , China , Cambridge , Cambridgeshire , Poland , Polish , America , American , Myung Ju Ahn , Daiichi Sankyo , Brendan Mcevoy , Weiguo Su , Cristian Massacesi , Chelsea Ford , Single Institution Study , World Health Organization , Sungkyunkwan University School Of Medicine , Lung Ambition Alliance , Nasdaq , Company On Twitter Astrazeneca , Astrazeneca , Samsung Medical Center , International Agency For Research On Cancer , Department Of Medicine , American Cancer Society , International Association , Lung Cancer , Sungkyunkwan University School , Principal Investigator , Chief Medical Officer , Oncology Chief Development Officer , Chief Executive Officer , Chief Scientific Officer , Prescribing Information , South America , Rare Diseases , From Tissue , Liquid Biopsy , Guide Treatment , Intj Mol , International Agency , Accessed July , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor , Histological Samples , Small Cell Lung Cancer , Systematic Review , Intj Clin Exp ,